Abstracts tagged "Disease Activity"

Abstract Number: 0893 • ACR Convergence 2020
Is It Feasible to Achieve Recommended Therapeutic Target Objective in Patients with Axial Spondyloarthritis in Clinical Practice? Data from the SpA-paz Cohort
Karen Franco Gomez¹, Chaimada Plasencia-Rodriguez¹, Marta Novella Navarro¹, Diego Benavent Nunez¹, Patricia Bogas¹, Romina Nieto², Irene Monjo³, Laura Nuño¹, Alejandro Villalba⁴, Diana Peiteado¹, Alejandro Balsa-Criado¹ and Victoria Navarro-Compán⁵, ¹HOSPITAL UNIVERSITARIO LA PAZ, MADRID, Spain, ²hospital intendente carrasco, Rosario, Argentina, ³Rheumatology, La Paz University Hospital- IdiPAZ, Madrid, Spain, ⁴Hospital La Paz - IdiPAZ, Madrid, Spain, ⁵Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain
Background/Purpose: to analyze the frequency of patients with axSpA achieving maintained remission (R) or low disease activity (LDA) after receiving biological therapy. Secondary objectives included:…
Abstract Number: 1168 • ACR Convergence 2020
Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma
Suzanne Li¹, Mara Becker², Sandy Hong³, Polly Ferguson⁴, Themba Nyrienda¹, Tracy Andrews⁵, Katie Stewart⁶, C. Egla Rabinovich⁷, Robert Fuhlbrigge⁸, Thomas Mason⁹, Elena Pope¹⁰, Maria Ibarra¹¹, Fatma Dedeoglu¹², Gloria Higgins¹³, Ronald Laxer¹⁴, Marilynn Punaro⁶, Kathryn Torok¹⁵ and CARRA Investigators¹⁶, ¹Hackensack University Medical Center, Hackensack, ²Duke University School of Medicine, Durham, NC, ³University of Iowa Stead Family Children's Hospital, Iowa City, IA, ⁴University of Iowa Carver College of Medicine, Iowa City, IA, ⁵Rutgers, Newark, ⁶UT Southwestern, Dallas, TX, ⁷Duke University Hospital, Durham, NC, ⁸University of Colorado, Denver, CO, ⁹Mayo Clinic, Rochester, MN, ¹⁰Hospital For Sick Kids, Toronto, ON, Canada, ¹¹Children's Mercy Kansas City, Kansas City, MO, ¹²Boston Children's Hospital, Boston, MA, ¹³Nationwide Childrens Hospital/ The Ohio State University, Columbus, OH, ¹⁴The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵University of Pittsburgh, Pittsburgh, PA, ¹⁶CARRA, Durham
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease. Treatment is directed towards controlling disease activity to minimize risk for functional impairment…
Abstract Number: 1299 • ACR Convergence 2020
Longitudinal Patterns of Anxiety Symptomology Among Patients with Systemic Lupus Erythematosus (SLE) Remain Stable over Time and Do Not Associate with SLE Disease Activity
Daphne Lew¹, Xinliang Huang², Sara Kellahan², Hong Xian³, Seth Eisen⁴ and Alfred Kim⁵, ¹Washington University in St. Louis School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University in St. Louis School of Medicine, St. Louis, ³Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, St. Louis, ⁴Washington University School of Medicine, St Louis, MO, ⁵Washington University School of Medicine, St. Louis, MO
Background/Purpose: Almost 40% of patients with SLE have comorbid mental health conditions.1 Though depression is most commonly reported (24% to 30%), many SLE patients also…
Abstract Number: 1597 • ACR Convergence 2020
Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and May Facilitate the Implementation of Treat to Target Therapy
Taylor Nelson¹, Gary Kunkel² and Grant Cannon², ¹University of Utah, Salt Lake City, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City
Background/Purpose: Rheumatoid Arthritis (RA) management guidelines recommend the collection of Disease Activity Measures (DAMs) to direct therapy as a component of a “treat-to-target” (T2T) strategy. …
Abstract Number: 1760 • ACR Convergence 2020
The Association Between the Risk of Venous Thromboembolism and Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Observational Study
Masaru Yoshimura¹, Yuichiro Fujieda², Michihito Kono², Masaru Kato², Kenji Oku², Olga Amengual² and Tatsuya Atsumi³, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an immune-mediated synovial disease with chronic inflammation. Systemic inflammation is considered one of risk factors for venous thromboembolism (VTE), which…
Abstract Number: 1887 • ACR Convergence 2020
Spinal Mobility and Function: How Closely Do They Associate in Axial Spondyloarthropathy?
Sinead Maguire¹, Phil Gallagher² and Finbar O'Shea¹, ¹St James' Hospital, Dublin, Ireland, ²St Vincents University Hospital, UCD, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is a form of inflammatory arthritis affecting the axial skeleton. Persistent disease activity can result in restricted spinal mobility over time,…
Abstract Number: 0042 • ACR Convergence 2020
Racial and Ethnic Differences in a Multiple Biochemical Measure of Rheumatoid Arthritis Disease Activity
Rahaf Baker¹, Jonathan Graf², Laura Trupin², Sarah Goglin³, Patricia Katz⁴, Jennifer Barton⁵, Jean Liew⁶ and Katherine Wysham⁷, ¹Highland Hospital Internal Medicine, Oakland, CA, ²UCSF, San Francisco, CA, ³University of California San Francisco, Burlingame, CA, ⁴University of California, San Francisco, Novato, CA, ⁵VAPORHCS/OHSU, Portland, OR, ⁶University of Washington, Seattle, WA, ⁷VA Puget Sound/University of Washington, Seattle, WA
Background/Purpose: Although management of RA has improved greatly over the past two decades with the advent of novel therapeutics, racial/ethnic and socioeconomic disparities persist. Traditional…
Abstract Number: 0266 • ACR Convergence 2020
The Correlation Between Pregnancy, Disease Activity and Adverse Pregnancy Outcomesin Patients with Systemic Lupus Erythematosus
Cigdem Cetin¹, Tugba Sarac Sivrikoz¹, Muge Ates Tıkız¹, Ege Sinan Torun¹, Sibel Zarali¹, Yasemin Yalcinkaya¹, Ahmet Gül¹, Murat İnanç¹, Mahdume Lale Öcal², İbrahim Kalelioğlu¹ and Bahar Artim Esen¹, ¹İstanbul Faculty of Medicine, İstanbul, Turkey, ²Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can present with acute disease flares/exacerbations during pregnancy and postpartum period1. These flares can cause adverse pregnancy outcomes…
Abstract Number: 0428 • ACR Convergence 2020
Enrichment of Clinical Trial Recruitment Using Advanced Molecular Imaging in Takayasu’s Arteritis
Kaitlin Quinn¹, Mark Ahlman², Emily Rose³, Peter Merkel⁴ and Peter C. Grayson⁵, ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ²National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ³Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Definitions of disease activity are not standardized in Takayasu’s arteritis (TAK), which can lead to difficulty in determining whether a patient should be enrolled…
Abstract Number: 0795 • ACR Convergence 2020
Minimum Clinically Important Improvement in Patients with Rheumatoid Arthritis Associates with Gut Microbiome
Vinod Gupta¹, Kevin Cunningham², Benjamin Hur¹, John Davis¹ and Jaeyun Sung¹, ¹Mayo Clinic, Rochester, MN, ²University of Minnesota, Minneapolis, MN
Background/Purpose: Within the past decade, there have been several major discoveries in cross-sectional gut microbiome studies suggesting that dysbiosis of the gut microbiota is a…
Abstract Number: 0900 • ACR Convergence 2020
Achievement of Low Disease Activity According to BASDAI with Ixekizumab in Patients with Axial Spondyloarthritis: 16-Week Results from the COAST Trials
Denis Poddubnyy¹, Xavier Juanola², Clément Prati³, Hagen Russ⁴, Yves Schymura⁴, Soyi Liu-Leage⁵, Mani Haschemi Nassab⁴ and Jean Dudler⁶, ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Rheumatology Service, University Hospital Bellvitge, IDIBELL, Barcelona, Spain, Barcelona, Spain, ³Service de Rhumatologie, Hôpital Jean-Minjoz , Besançon, France, Besançon, France, ⁴Eli Lilly and Company, Indianapolis, Indiana, USA, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Rheumatology, HFR Fribourg - Hospital Cantonal, Fribourg, Switzerland, Fribourg, Switzerland
Background/Purpose: The efficacy of ixekizumab (IXE), a selective interleukin-17A antagonist, was assessed in patients (pts) with axial SpA (axSpA) in three Phase 3, randomized, double-blind,…
Abstract Number: 1180 • ACR Convergence 2020
External Validation of a Multi-biomarker-Based Cardiovascular Disease Risk Prediction Score for Rheumatoid Arthritis Patients
Jeffrey R Curtis¹, Eric Sasso², Elena Hitraya², Cheryl Chin³, Richard Bamford³, Rotem Ben-Shachar³, Alexander Gutin³, Darl Flake³, Brent Mabey³ and Jerry Lanchbury³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Myriad Autoimmune, South San Francisco, CA, ³Myriad Genetics, Inc., Salt Lake City, UT
Background/Purpose: A novel score for predicting 3-year risk for CVD events in RA patients combines age, four traditional CVD risk factors (diabetes, hypertension, smoking, history…
Abstract Number: 1308 • ACR Convergence 2020
The Presence of Spondyloarthritis Is Associated with Higher Clinical Disease Activity in Patients with Early Crohn’s Disease: Results of a Prospective Cohort Study
Valeria Rios Rodriguez¹, Mikhail Protopopov¹, Fabian Proft¹, Susanne Lüders¹, Judith Rademacher¹, Hildrun Haibel¹, Maryna Verba¹, Joachim Sieper¹, Elena Sonnenberg¹, Lea Isabell Kredel¹, Michael Schumann¹, Britta Siegmund¹ and Denis Poddubnyy², ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Inflammatory bowel disease (IBD) and specifically Crohn’s disease (CD) is known to be associated with spondyloarthritis (SpA) (1). However, only little is known about…
Abstract Number: 1603 • ACR Convergence 2020
P4 Index Correlates with RAPID3 and Disease-Specific Indices in Rheumatoid Arthritis (RA) and Axial Spondyloarthritis (axSpA)
Abhijeet Danve¹, Betty Hsiao² and Phillip Zhang³, ¹Yale University, Rocky Hill, CT, ²Yale Rheumatology, New Haven, ³Yale University, New Haven, CT
Background/Purpose: RAPID3 scores correlate well with disease-specific indices, including the Clinical Disease Activity Index (CDAI) in RA and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)…
Abstract Number: 1770 • ACR Convergence 2020
Lupus Low Disease Activity State Protects Against Pre-Term Birth
Michelle Petri¹, Jessica Li² and Daniel Goldman³, ¹Johns Hopkins University School of Medicine, Baltimore, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Lupus low disease activity state (LLDAS) (Ann Rheum Dis. 2016;75:1615–21.) combine both low disease activity (SLEDAI score of ≤4, PGA >=1 no flare, no…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].